CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis

BACKGROUND: Ocrelizumab maintains B-cell depletion via six-monthly dosing. Whilst this controls relapsing multiple sclerosis, it also inhibits seroconversion following SARS-CoV-2 vaccination unlike that seen following alemtuzumab and cladribine treatment. Emerging reports suggest that 1–3% B-cell re...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, David, MacDougall, Amy, Kang, Angray S., Schmierer, Klaus, Giovannoni, Gavin, Dobson, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642825/
https://www.ncbi.nlm.nih.gov/pubmed/34902760
http://dx.doi.org/10.1016/j.msard.2021.103448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642825/
https://www.ncbi.nlm.nih.gov/pubmed/34902760
http://dx.doi.org/10.1016/j.msard.2021.103448

Ejemplares similares